Price
$3.95-33.28%Social Signal Score
Analyst Ratings
30 analystsRevenue
$652.52M+983.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Seth Barrie Blackley
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 4,200
- Beta
- 0.84
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.42
Financials
Revenue
$652.52M+983.7%Net Income
$-28.36MEBITDA
$12.78MFree Cash Flow
$-23.55M-680.5%EPS (diluted)
$-0.25Shares Outstanding (diluted)
112.54M+161.1%Operating Expenses
$68.83MCash & Debt
$115.70MReturn of Capital
$0.00Revenue by Segment (annual)
$1.88BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.88B | $-534.51M | $-5.07 |
| 2024 | $2.55B | $-61.62M | $-0.81 |
| 2023 | $1.96B | $-113.04M | $-1.28 |
| 2022 | $1.35B | $-19.16M | $-0.20 |
| 2021 | $907.96M | $-37.60M | $-0.36 |
| 2020 | $924.64M | $-334.25M | $-3.94 |
| 2019 | $687.12M | $-301.97M | $-3.71 |
| 2018 | $627.06M | $-52.66M | $-0.68 |
| 2017 | $434.95M | $-60.66M | $-0.94 |
| 2016 | $254.19M | $-159.74M | $-3.55 |
| 2015 | $96.88M | $332.49M | $8.03 |
| 2014 | $0.00 | $-25.25M | $-0.66 |
| 2013 | $25.67M | $20.02M | $0.06 |
| 2012 | $8.35M | $-19.26M | $-0.50 |
Valuation
EVHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·5h ago·Neutral
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, before market open, with a conference call to follow at 8:30 a.m. ET. Shareholders and interested participants may listen to a live broadcast of …
View source ↗ - Newsseekingalpha.com·57d ago·Neutral
Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.
View source ↗ - Newsmarketbeat.com·62d ago·Neutral
Evolent Health Q2 Earnings Call Highlights Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.06 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.02 vs $-0.01beat
- Thu, May 7$-0.02 vs $-0.05beat
- Tue, Feb 24$0.08 vs $0.06beat
- Thu, Nov 6$0.05 vs $0.10miss
- Thu, Aug 7$-0.10 vs $0.09miss
- Thu, May 8$0.06 vs $0.09miss
Estimates and results for EVH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EVH officers and directors.
- Bought
- $1.4m
- Sold
- $1.4m
12 trades
5 trades
- Mccarthy Daniel Josephsold
- Springstubb Brendan Bbought
- Jelinek Richard Mbought
- Jelinek Richard Mbought
- Springstubb Brendan Bbought
- Keck Kimbought
- Holder Dianebought
- Mccarthy Daniel Josephbought
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Greg Gianfortehouse · MT00 · disclosed May 29, 2020 (18d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Nov 27, 2019 (47d later)Buy$100,001 - $250,000
- Greg Gianfortehouse · MT00 · disclosed Oct 20, 2019 (40d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (34d later)Buy$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Jun 15, 2018 (8d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.